Oricell moved its GPC3-targeted immune cell strategy into confirmatory development for liver cancer. The company’s autologous CAR T therapy, Ori-C101, is entering a registration-focused phase II trial for patients with GPC3-positive advanced hepatocellular carcinoma, aiming to establish a confirmatory evidence base. The program is positioned as the first GPC3-directed immune cell therapy and the first CAR T therapy specifically reaching confirmatory-stage development in liver cancer. That stage shift matters in a field where manufacturing complexity and durable response proof are typically decisive. If the trial supports registration outcomes, Ori-C101 could become a reference point for antigen-directed CAR T approaches in solid tumors.